Point72 Asset Management
ANAB icon

Point72 Asset Management’s AnaptysBio ANAB Stock Holding History

Point72 Asset Management’s Portfolio ANAB Stock Details ANAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-20,000
Closed -$2M – 947
2018
Q3 		$2M Buy
+20,000
New +$1.66M 0.01% 761

Other funds holding ANAB

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Point72 Asset Management's ANAB Position: Q1 2026 in Review

Point72 Asset Management reduced its AnaptysBio (ANAB) stake by 97% in Q1 2026, selling an estimated $101M and leaving 55,303 shares worth $3.07M. The position accounts for ﹤0.01% of the portfolio, ranked #2029.

Point72 Asset Management first reported a position in ANAB in Q1 2019 and has held it in 21 quarters since. The position peaked at $93.7M in Q4 2025. 207 funds tracked by Wall St. Rank hold ANAB as of Q1 2026.

  • Point72 Asset Management held 55,303 shares of AnaptysBio worth $3.07M as of Q1 2026.
  • Point72 Asset Management sold 1,877,587 AnaptysBio shares in Q1 2026, an estimated $101M.
  • AnaptysBio made up ﹤0.01% of Point72 Asset Management's portfolio in Q1 2026, its #2029 holding.
  • Point72 Asset Management first reported a position in AnaptysBio in Q1 2019 and has held it in 21 quarters since.
  • Point72 Asset Management's AnaptysBio position peaked at $93.7M in Q4 2025.
  • 207 funds tracked by Wall St. Rank held AnaptysBio as of Q1 2026.

Based on Point72 Asset Management's 13F filing for Q1 2026, filed 15 May 2026.